DDInter856 DDInter1763
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Temsirolimus {u} (Compound) treats {v} (Disease) kidney cancer
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
Temsirolimus {u} (Compound) upregulates {v} (Gene) MICU1
Temsirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Temsirolimus {u} (Compound) downregulates {v} (Gene) TFDP1
Temsirolimus {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Temsirolimus (Compound) resembles Everolimus (Compound)
Temsirolimus (Compound) treats kidney cancer (Disease)
Temsirolimus (Compound) binds CYP3A4 (Gene)
Temsirolimus (Compound) upregulates MICU1 (Gene)
Temsirolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Temsirolimus (Compound) downregulates TFDP1 (Gene)
Temsirolimus (Compound) causes Febrile neutropenia (Side Effect)